ES2061252T3 - Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. - Google Patents

Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.

Info

Publication number
ES2061252T3
ES2061252T3 ES91911446T ES91911446T ES2061252T3 ES 2061252 T3 ES2061252 T3 ES 2061252T3 ES 91911446 T ES91911446 T ES 91911446T ES 91911446 T ES91911446 T ES 91911446T ES 2061252 T3 ES2061252 T3 ES 2061252T3
Authority
ES
Spain
Prior art keywords
antitusive
mucosa
regulator
procedure
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91911446T
Other languages
English (en)
Spanish (es)
Inventor
Giuseppe Quadro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mediolanum Farmaceutici SpA
Original Assignee
Mediolanum Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11168835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2061252(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mediolanum Farmaceutici SpA filed Critical Mediolanum Farmaceutici SpA
Application granted granted Critical
Publication of ES2061252T3 publication Critical patent/ES2061252T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES91911446T 1990-06-06 1991-06-03 Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. Expired - Lifetime ES2061252T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02056290A IT1248702B (it) 1990-06-06 1990-06-06 Agente antitussivo e mucoregolatore,sua preparazione e composizioni farmaceutiche

Publications (1)

Publication Number Publication Date
ES2061252T3 true ES2061252T3 (es) 1994-12-01

Family

ID=11168835

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91911446T Expired - Lifetime ES2061252T3 (es) 1990-06-06 1991-06-03 Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.

Country Status (9)

Country Link
US (1) US5352703A (OSRAM)
EP (1) EP0532644B1 (OSRAM)
JP (1) JPH05506450A (OSRAM)
AT (1) ATE113029T1 (OSRAM)
CA (1) CA2083597A1 (OSRAM)
DE (1) DE69104723T2 (OSRAM)
ES (1) ES2061252T3 (OSRAM)
IT (1) IT1248702B (OSRAM)
WO (1) WO1991018865A1 (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CN104350041A (zh) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 用于治疗神经系统疾病的组合物和方法
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
AU2013264894B2 (en) 2012-05-23 2015-11-19 Cellix Bio Private Limited Compositions and methods for treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN107428697A (zh) 2015-01-06 2017-12-01 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1432904A (en) * 1973-08-24 1976-04-22 Uriach & Cia Sa J N-2-n-cyclohexyl-n-methylaminomethyl-4,6-dibromo-phenyl-benzamides methods for their preparation and compositions containing them
FR2399276A1 (fr) * 1977-08-03 1979-03-02 Rhone Poulenc Ind Procede de fabrication de billes d'alumine
EP0004026B1 (de) * 1978-03-02 1982-05-05 Ciba-Geigy Ag Hydrolysestabile, ortho-alkylierte Phenylphosphonite und stabilisierte Massen
IT1094864B (it) * 1978-05-29 1985-08-10 Tosi Franco Ist Derivati della bromexina e procedimento per la loro preparazione
DK110582A (da) * 1981-03-19 1982-09-20 Hokuriku Pharmaceutical 2-benzoylamino-substituerede benzylaminderivater samt fremgangsmaade til fremstilling af samme
IT1213132B (it) * 1984-02-02 1989-12-14 Yason Srl Agente antibroncopneumopatico.

Also Published As

Publication number Publication date
IT9020562A0 (OSRAM) 1990-06-06
DE69104723D1 (de) 1994-11-24
JPH05506450A (ja) 1993-09-22
EP0532644B1 (en) 1994-10-19
ATE113029T1 (de) 1994-11-15
CA2083597A1 (en) 1991-12-07
US5352703A (en) 1994-10-04
IT9020562A1 (it) 1991-12-06
EP0532644A1 (en) 1993-03-24
DE69104723T2 (de) 1995-02-23
WO1991018865A1 (en) 1991-12-12
IT1248702B (it) 1995-01-26

Similar Documents

Publication Publication Date Title
ES2061252T3 (es) Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
DE3581819D1 (de) Pyridazinamine wirksam gegen viren.
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ES2075202T3 (es) Nuevas arilpiridazinas, su preparacion, su utilizacion, y medicamentos que las contienen.
DK0656207T4 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
MX9206541A (es) Derivados de acido acetico, procedimiento para su preparacion y composicion farmaceutica que los contiene.
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
PT758248E (pt) Formulacoes para o factor ix
MX9202289A (es) Nuevos derivados de tiopiranopirrol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9204354A (es) Compuestos heterociclicos de 5 miembros, procedimiento para prepararlos y composiciones farmaceuticas que los contienen.
MX9205208A (es) Compuestos derivados del acido 5-amino-4-hidroxihexanoico, procedimiento para su preparacion y compociciones farmaceuticas que los contienen
GR1000392B (el) Σταθεροποιημενες συνθεσεις περιεχουσες επιδερμικο παραγοντα αναπτυξης.
ES8603870A1 (es) Un procedimiento para la preparacion de derivados de 2,2'-iminobisetanol.
NO952321D0 (no) Polypeptid, samt anti-HIV-preparat fremstilt fra dette
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
MX9207394A (es) Esteroides de 17-espirofuran-3'-ilideno.
PT952974E (pt) Derivados bifenilicos substituidos por um radical aromatico ou heteroaromatico e composicoes farmaceuticas e cosmeticas que os contem
MX9202544A (es) Compuestos de diaminoftalimidas substituidas y analogas, procedimiento para su preparacion y preparados farmaceuticos que los contienen.
NO972623D0 (no) Framasöytisk blanding omfattende lamotrigin
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
NO950177D0 (no) Farmakologisk aktive erivater
DK0632717T3 (da) Middel til anvendelse som et anti-irritationsmiddel
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 532644

Country of ref document: ES